Efficacy of Oral Acetazolamide on Decongestion in Patients With Heart Failure

Phase 3

Recruiting

• Conditions: Chronic congestive heart failure.; Chronic combined systolic (congestive) and diastolic (congestive) heart failure; I50.42

• Registration Number: IRCT20230527058306N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 25 July 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

Earn at least 8 points from EVEREST score
Patients over 18 years old
The main clinical sign of volume overload includes edema, ascites confirmed by abdominal ultrasound
Pleural effusion confirmed by chest X-ray or chest ultrasound without intravenous furosemide
Maintenance treatment with oral furosemide as a loop diuretic =20 mg for at least one month
Using SGLT2i drugs including canagliflozin, dapagliflozin, and empagliflozin for at least one month

Exclusion Criteria

Systolic blood pressure less than 90 mmHg or mean arterial pressure less than 65 mmHg
Estimated glomerular filtration rate (eGFR) <20 ml/min/1.73 m2
Using any diuretic agent except mineralocorticoid receptor antagonists including spironolactone and eplerenone
Simultaneous diagnosis of acute coronary syndrome, which is characterized by typical chest pain in addition to an increase in troponin level above the 99th percentile or electrocardiographic changes indicating ischemia or hospitalization as unstable angina.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Random urine sodium to creatinine ratio. Timepoint: The third day of study. Method of measurement: Urine and blood tests.

Secondary Outcome Measures

Name	Time	Method
B-type natriuretic peptide. Timepoint: Thirty days of study. Method of measurement: Blood test.